These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11228378)

  • 1. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.
    Byun Y; Ohmura M; Fujihashi K; Yamamoto S; McGhee JR; Udaka S; Kiyono H; Takeda Y; Kohsaka T; Yuki Y
    Vaccine; 2001 Feb; 19(15-16):2061-70. PubMed ID: 11228378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice.
    Zhang XH; He KW; Zhang SX; Lu WC; Zhao PD; Luan XT; Ye Q; Wen LB; Li B; Guo RL; Wang XM; Lv LX; Zhou JM; Yu ZY; Mao AH
    Vaccine; 2011 May; 29(22):3923-9. PubMed ID: 21338683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization of cocktail/fusion protein containing Tir along with ΔG active fragment of Zot as mucosal adjuvant confers enhanced immunogenicity and reduces E. coli O157:H7 shedding in mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Int Immunopharmacol; 2018 Oct; 63():211-219. PubMed ID: 30103196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.
    Kuribayashi T; Seita T; Fukuyama M; Furuhata K; Honda M; Matsumoto M; Seguchi H; Yamamoto S
    J Infect Chemother; 2006 Oct; 12(5):251-6. PubMed ID: 17109087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Med Microbiol Immunol; 2019 Feb; 208(1):89-100. PubMed ID: 30209565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin.
    Tsuji T; Shimizu T; Sasaki K; Shimizu Y; Tsukamoto K; Arimitsu H; Ochi S; Sugiyama S; Taniguchi K; Neri P; Mori H
    Vaccine; 2008 Jan; 26(4):469-76. PubMed ID: 18093704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization of mice with Lactococcus lactis expressing Shiga toxin truncate confers enhanced protection against Shiga toxins of Escherichia coli O157:H7 and Shigella dysenteriae.
    Sreerohini S; Balakrishna K; Parida M
    APMIS; 2019 Oct; 127(10):671-680. PubMed ID: 31344276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization.
    Imai Y; Nagai R; Ono Y; Ishikawa T; Nakagami H; Tanikawa T; Kurohane K
    Infect Immun; 2004 Feb; 72(2):889-95. PubMed ID: 14742533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
    Ohmura M; Yamamoto M; Kiyono H; Fujihashi K; Takeda Y; McGhee JR
    Vaccine; 2001 Dec; 20(5-6):756-62. PubMed ID: 11738739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
    J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori.
    Xing Y; Liu W; Li X; Guo L; Lv X; Xi T
    Biochem Biophys Res Commun; 2015 Jul; 462(3):269-74. PubMed ID: 25957472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model.
    Guo L; Yin R; Liu K; Lv X; Li Y; Duan X; Chu Y; Xi T; Xing Y
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3495-507. PubMed ID: 24370888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis.
    Zhang P; Yang QB; Balkovetz DF; Lewis JP; Clements JD; Michalek SM; Katz J
    Vaccine; 2005 Sep; 23(39):4734-44. PubMed ID: 15955601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.
    Smith MJ; Teel LD; Carvalho HM; Melton-Celsa AR; O'Brien AD
    Vaccine; 2006 May; 24(19):4122-9. PubMed ID: 16551486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.
    Wu HY; Russell MW
    Vaccine; 1998; 16(2-3):286-92. PubMed ID: 9607044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice.
    Lin R; Zhu B; Zhang Y; Bai Y; Zhi F; Long B; Li Y; Wu Y; Wu X; Fan H
    Microb Pathog; 2017 Apr; 105():19-24. PubMed ID: 28163157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.